-
Red yeast rice and therapeutic lifestyle changes decrease LDL-cholesterol levels without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.
-
A study group in Greece used 3 consecutive different regimens to achieve a 98% eradication rate among 540 patients not lost to follow-up. The success of each individual regimen was about 70%.
-
A new antiplatelet drug has been approved by the FDA for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
-
Hidradenitis suppurativa (HSP) is regarded both in the dermatology and primary care communities as a "heart sink" diagnosis: Patients are generally chronically burdened, we have little successful treatment, the pathophysiology is poorly understood, and the consequences often have an important negative impact on quality of life.
-
Patients who receive proton-pump inhibitors in the hospital are at increased risk for hospital-acquired pneumonia.
-
The combination of a CBC and a BMP can predict death.
-
Obstructive sleep apnea (OSA) is inextricably linked with adverse cardiovascular events including stroke, MI, hypertension (HTN), and arrhythmia.
-
A new opioid analgesic with a dual mechanism of action has been released for market by PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
-
The ECG in the tracing above was obtained from a 68-year-old man who presented with a history of fatigue for the past 3 weeks, but no chest pain. No history of coronary artery disease, and no prior tracings were available for comparison. How would you interpret his ECG in view of this clinical history?
-
Comparing blood pressure medications, determining optimal length of androgen-deprivation therapy, red yeast rice for LDL reduction, and FDA Actions.
